Browse Subject Areas

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Cost-Effectiveness of Quantiferon®-TB Gold-In-Tube Versus Tuberculin Skin Testing for Contact Screening and Treatment of Latent Tuberculosis Infection in Brazil

Cost-Effectiveness of Quantiferon®-TB Gold-In-Tube Versus Tuberculin Skin Testing for Contact Screening and Treatment of Latent Tuberculosis Infection in Brazil

  • Ricardo Ewbank Steffen, 
  • Rosângela Caetano, 
  • Márcia Pinto, 
  • Diogo Chaves, 
  • Rossini Ferrari, 
  • Mayara Bastos, 
  • Sandra Teixeira de Abreu, 
  • Dick Menzies, 
  • Anete Trajman



Latent tuberculosis infection (LTBI) is a reservoir for new TB cases. Isoniazid preventive therapy (IPT) reduces the risk of active TB by as much as 90%, but LTBI screening has limitations. Unlike tuberculin skin testing (TST), interferon-gamma release assays are not affected by BCG vaccination, and have been reported to be cost-effective in low-burden countries. The goal of this study was to perform a cost-effectiveness analysis from the health system perspective, comparing three strategies for LTBI diagnosis in TB contacts: tuberculin skin testing (TST), QuantiFERON®-TB Gold-in-Tube (QFT-GIT) and TST confirmed by QFT-GIT if positive (TST/QFT-GIT) in Brazil, a middle-income, high-burden country with universal BCG coverage.

Methodology/Principal Findings

Costs for LTBI diagnosis and treatment of a hypothetical cohort of 1,000 adult immunocompetent close contacts were considered. The effectiveness measure employed was the number of averted TB cases in two years. Health system costs were US$ 105,096 for TST, US$ 121,054 for QFT-GIT and US$ 101,948 for TST/QFT-GIT; these strategies averted 6.56, 6.63 and 4.59 TB cases, respectively. The most cost-effective strategy was TST (US$ 16,021/averted case). The incremental cost-effectiveness ratio was US$ 227,977/averted TB case for QFT-GIT. TST/QFT-GIT was dominated.


Unlike previous studies, TST was the most cost-effective strategy for averting new TB cases in the short term. QFT-GIT would be more cost-effective if its costs could be reduced to US$ 26.95, considering a TST specificity of 59% and US$ 18 considering a more realistic TST specificity of 80%. Nevertheless, with TST, 207.4 additional people per 1,000 will be prescribed IPT compared with QFT.


According to the World Health Organization (WHO), in 2010 an estimated 8.8 million people were infected with tuberculosis (TB), with the disease being responsible for 1.4 million deaths [1]. Even though disease incidence and mortality have been declining steadily, no less than one third of the world population has latent TB infection (LTBI) [2]. To meet WHO's goal of eliminating the disease by 2050, new approaches to reduce this vast reservoir of LTBI are needed [3]. Recently infected individuals have a high risk of developing active TB during the first two years following infection [4]. This risk can be reduced by as much as 90% with isoniazid preventive therapy (IPT) among those who adhere to the full regimen. [5], [6] However, current preventive treatment regimens are lengthy and require close monitoring of side effects, so adherence to a full course of treatment is often suboptimal [5], [7]. Therefore, it is essential to properly identify those individuals who actually have LTBI, and new diagnostic techniques are being evaluated for this purpose.

The most studied and widely used test for the diagnosis of LTBI, the tuberculin skin test (TST), is based on Robert Koch's description of the tuberculin, and has been available for over a century [8], [9]. TST might give false positive results due to previous BCG vaccination and to non-tuberculous mycobacteria (NTM) infection [10], [11], [12]. These are pressing issues in subtropical, high-burden countries, where BCG vaccination is implemented and NTM infections are prevalent [10]. Moreover, a TST might remain positive many decades after infection,[13] and cannot distinguish remote from recent infection, which has a higher risk of progression to active TB. [14] False positive tests will result in more subjects undergoing IPT, increasing costs with follow-up and adverse events, mainly severe drug-induced liver injury (DILI). Finally, TST requires at least two visits, which increase patients' costs and possible loss of result reading.

Newer interferon-gamma release assays (IGRA) have the advantage of using specific M. tuberculosis antigens, which appear to provide a higher specificity [15]. However, IGRA tests require equipment and consumables that translate into high costs for the health system.

Studies in high-income, low TB burden countries have suggested that three different commercially available IGRA tests are cost-effective in distinct populations [16], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27]. Many of these countries have incorporated IGRA tests in their routine guidelines [28]. In recently revised guidelines, the Brazilian National TB Program (NTP) recommended screening all contacts in cities where the incidence rate is under 50/100,000 inhabitants, as the national overall TB incidence rate has been reduced to 37/100,000 inhabitants [29]. IGRA tests have not been incorporated in these guidelines because no health economic evaluations of these tests in high-burden countries with broad BCG coverage are available. Moreover, previous cost-effectiveness analyses have attributed a very low specificity to the tuberculin skin test in BCG-vaccinated individuals,[20], [22], [24] although BCG vaccination in infancy, which is the standard practice in Brazil,[29], [30] is unlikely to result in a positive test in adults [12].

The aim of the present study was to perform a cost-effectiveness analysis from the health system perspective, comparing three different strategies for screening and treating LTBI in Brazil: TST alone, QuantiFERON TB® Gold in-Tube (QFT-GIT), and TST followed by QFT-GIT confirmation when the former is positive (QFT-GIT/TST).


Model structure

We conducted an economic analysis considering a hypothetical cohort of 1,000 immunocompetent 35-year-old close contacts of TB index cases followed for two years after LTBI diagnosis, since this is the period when the risk of developing active TB is greatest. A decision-tree analysis using the TreeAge ProTM 2011 (TreeAge Software Inc., Williamstown, MA, USA) was built and three strategies for detecting LTBI in contacts were compared: (i) TST alone, as presently recommended by the Brazilian National TB Program (NTP); (ii) QFT-GIT, the only IGRA presently approved by the National Health Surveillance Agency (ANVISA) in the country; and (iii) TST/QFT-GIT, a strategy found to be more cost-effective in some high-income countries and recommended by guidelines for screening LTBI in many of them [28]. Figure 1 displays the TST strategy subtree of the analytic decision model.

Figure 1. Decision subtree diagram of the Tuberculin Skin Testing screening strategy for LTBI immunocompetent adult contacts.

Model parameters

The proportion of TST-positive contacts, and the sensitivity and specificity of the tests were derived from two systematic reviews [15], [31]. The rate of progression to disease and other parameters necessary for the analysis were based on the existing literature (see Table 1).

Table 1. Modeling inputs, assumptions and ranges used in sensitivity analyses for a hypothetical cohort of 1,000 adult immunocompetent contacts in Brazil.

Model assumptions

We assumed that (i) all contacts are asymptomatic and there are no baseline active cases of TB; (ii) there are no HIV-infected individuals in the cohort; (iii) all LTBI and TB cases are from a fully drug-sensitive strain; (iv) 10% of subjects with LTBI and a positive TST were recently infected (TST conversion); (v) 10% of subjects submitted to TST do not return for reading; (vi) all patients diagnosed with LTBI are prescribed IPT after a clinical examination and a chest radiograph to exclude active TB, (vii) patients undergoing IPT who develop DILI are assumed to have completed only four weeks of IPT, which is insufficient to prevent progression to active TB; (viii) IPT is 90% efficient in fully adherent patients and inefficient in the less than fully adherent; (ix) only 50% of patients are fully adherent to IPT; (x) TB cases are managed under directly observed treatment (DOT).

Effectiveness measure

The number of averted new TB cases was chosen as the measure of effectiveness. We also compared the number necessary to treat (NNT) with each of the three strategies, and those NNTs were incorporated in the treatment costs.


The costs for screening and treatment were analyzed from the National Health System perspective, which is responsible for the funding of TB diagnosis and treatment in Brazil. We considered supplies, equipment, and human resources. All costs were converted to USA dollars (US$) at the rate of 1.76 reais/1 US$, the average conversion rate for 2010. No discounting was applied because of the short horizon of the study (two years). Inflation rate adjustment was not performed.

For a rigorous comparison of the strategies, a micro-costing analysis was carried out for both TST and QFT-GIT, since there are no reference values established for QFT-GIT in the Brazilian National Health System. The value of the QFT-GIT test kit was derived from the market price in Brazil.

In addition to the direct costs with tests, screening costs included one medical visit and one chest radiograph (CXR) when TST or QFT-GIT was positive, to exclude active TB. Costs of IPT included 300 mg of daily isoniazid for nine months and five follow-up visits. A partial treatment cost of IPT was considered for those who do not complete treatment and included the initial diagnostic workup, 2 months of isoniazid treatment and two follow-up visits. Costs of DILI were incorporated into the IPT treatment costs, assuming a 1% incidence rate, and included two additional clinic visits, two complete blood counts and liver function tests, in addition to hospitalization costs in 0.01% of DILI cases (Table 2) [4], [32].

Table 2. Cost analysis of screening and treatment of LTBI in Brazil, 2010.

The costs of supplies and drugs were obtained from public Ministry of Health sources, as were the costs of tests and hospitalization. Costs of follow-up visits for LTBI and TB treatment were derived from previous studies [33], [34]. Equipment costs were valued using the life-cycle cost method [35]. Equipment maintenance was also included in cost calculation. Time logs for each activity were recorded during routine practice. Items and values of costs are detailed in Table 2. The incremental cost-effectiveness ratio (ICER) was calculated using the least expensive strategy as the comparator. [36] Life span was defined as 20 years.

An extrapolation of costs and TB cases averted per year, considering the TB incidence in Brazil and an average of 4 contacts per TB case [31], regardless of the TB incidence rate in the area, was performed.

Sensitivity analysis

We performed one-way and two-way deterministic sensitivity analyses to test the robustness of results varying the parameters with a significant degree of uncertainty: TST and QFT-GIT sensitivity and specificity, LTBI and TB treatment costs (considering self-administered and DOT), prevalence of LTBI, rate of progression to active TB from recent and remote TB infection, costs of QFT-GIT, IPT completion rate. The ranges are displayed in Tables 1 and 2.

The study was approved by the Brazilian National Ethical Committee (CONEP 572/09).


Test costs were US$ 10.56 per TST and US$ 48.26 per QFT-GIT, mostly due to supplies (tuberculin and QFT-GIT test kit). Health system costs for screening and treating 1,000 contacts were US$ 105,096 for TST alone, US$ 121,054 for QFT-GIT alone and US$ 101,948 for TST/QFT-GIT (Table 3).

Table 3. Effectiveness and total costs (in US$) for screening and treating a hypothetical cohort of 1,000 adult immunocompetent TB contacts in Brazil, 2010.

During the two years following contact, TST alone averted 6.56 new TB cases, QFT-GIT alone averted 6.63 and TST/QFT-GIT averted 4.59. The number necessary to treat LTBI to avert one new TB case was 73.5, 41.9 and 39.5, respectively. The number of subjects undergoing IPT was highest on the TST strategy (482.4), followed by the QFT-GIT strategy, with 277.5 and TST followed by QFT-GIT, with 181.2. The number of subjects undergoing treatment were 482.4, 277.5 and 181.2, respectively (Table 3).

TST was the most cost-effective strategy (US$ 16,021/averted case, Table 3), followed by TST/QFT-GIT (US$ 18,259) and QFT-GIT alone (US$ 22,211). ICER was US$227,977/averted case for the QFT-GIT strategy. The TST/QFT-GIT strategy was dominated.

Considering the Brazilian present incidence of around 70,000 TB [37] cases per year and an average of 4 investigated contacts per case [31], the most cost-effective strategy (TST) would incur in a total cost of US$ 29,406,880 for the Health System and the prevention of 1,837 new TB cases/year in the country. Incorporating the QFT-GIT would cost an extra US$ 4,468,240 to avoid 19.6 extra cases/year.

In one-way sensitivity analysis, we found two variables to be important: TST specificity and QFT costs. In a two-way sensitivity analysis varying QFT costs and TST specificity, the QFT strategy became more cost-effective than TST if its costs were US$ 26.95 considering a TST specificity of 59% and US$ 18 considering a more realistic specificity of 80% (Figure 2). Other variables did not substantially affect our results and are shown in a tornado diagram (Figure 3).

Figure 2. Two-way sensitivity analysis of QFT-GIT costs at different TST specificities.

The red-shaded area represents the values where the QFT-GIT only strategy is more costly. The blue-shaded area represents the values where the TST only strategy is more costly. QFT strategy became less costly than TST if its costs were US$ 26.95 considering a TST specificity of 59% and US$ 18 considering a more realistic specificity of 80%.

Figure 3. Tornado diagram for Tuberculin Skin Testing versus QuantiFERON® Gold-In-Tube as the screening strategy for LTBI.

Termini of bars represent the incremental cost-effectiveness ratio (incremental cost/averted TB case) at the low and high assumption values for the different variables. Longer bars represent parameters to which the model is more sensitive.


Newer health technologies often bring new costs, requiring cost-effectiveness studies before they are incorporated into the health system. Their implementation is justified if effectiveness outweighs the higher costs [38]. IGRA tests have replaced or have been added to TST in developed countries, because they appear to be more specific and were considered cost-effective [16], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], [39]. The present study was designed to evaluate the cost-effectiveness of these strategies in a population in which TST specificity is thought to be lower than the specificity of IGRA. Unlike most of the previous cost-effectiveness analyses, [16], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], [39] we observed that TST was the most cost-effective strategy. Since the effectiveness of TST and QFT in preventing one TB case is very similar, replacing the TST with QFT becomes a question of relative costs of TST and the additional IPTs versus the costs of QFT. In Brazil, QFT-GIT is bought in the international market at relatively high costs and TST and IPT involve mostly labor costs, which are relatively low.

Our findings are similar to those of only one study, in which targeted testing using only the TST was considered to be more cost-effective than using QFT-GIT or T-SPOT®.TB, although these results were not maintained in sensitivity analyses[40].

The advantage of QFT-GIT in other studies was related to savings with patient evaluation and treatment for TB and IPT. However, health system costs in Brazil are considerably lower than those reported in other countries, and these lower costs had substantial impact in our results. TB treatment costs in our study were derived from the literature [33] and sensitivity analyses considered a range that included costs with self-administered and DOT treatment [34]. Our findings remained consistent in this sensitivity analysis. Regarding IPT costs, TST remained the dominant strategy within the range analyzed (US$ 46-141.35), but QFT-GIT would be more cost-effective if IPT costs were above US$ 332. However, it is unreasonable to suppose that IPT costs would be more than half the cost for active TB treatment. In most similar studies, IPT costs were between 2 and 7% of the TB treatment costs [16], [17], [19], [20], [22], [23], [24], [25], [26], [27], [41], [42] DILI costs arbitrated in our study were low when compared to the literature [16], [17], [19], [20], [22], [23], [24], [25], [26], [27], [41], [42]. Since the probability of severe adverse events in this population is low (young cohort and low adherence), the impact of DILI costs on the overall costs was minimal. Because DILI costs were incorporated into the overall IPT costs, this was accounted for in the sensitivity analysis. Besides costs with DILI, a low adherence to IPT reduces the overall IPT costs.

Another possible explanation for our contrasting findings is the specificity of TST, considered in other studies to be as low as 15% in the base case [22]. There is a general misconception that BCG vaccination has a high impact on TST false positive results. While this is true when subjects are vaccinated after 2 years of age, it is very unlikely that a TST-positive test in an adult contact who was BCG-vaccinated at birth results from that vaccination rather than from LTBI [12]. We used the pooled TST specificity for BCG-vaccinated populations described in a meta-analysis (59%) [15]. However, this meta-analysis included six studies in four countries where BCG is used after infancy [30]. The current practice in Brazil is one vaccination at birth, and the specificity of TST is probably much higher, justifying a range of up to 90% and not less than 59% in our sensitivity analysis. Using a higher TST specificity in this population would make the TST strategy appear more cost-effective than in the base-case scenario.

An universal limitation of economic analyses of LTBI detection and treatment is related to the sensitivity of tests: since there is no golden standard for LTBI, they are based on studies performed in populations with active TB, in whom TST and IGRA tests, which are based on immune response, have probably lower sensitivity [15]. However, this limitation affects equally both tests. Although we considered a higher sensitivity for TST than for QFT, as found in the meta-analysis,[15] the loss of reading of TST decreased its effectiveness.

In addition to the tests' accuracy, previous studies were also sensitive to LTBI prevalence, a parameter with a high degree of uncertainty. Prevalence of LTBI is generally estimated by TST surveys, and there is a very wide variation in the prevalence of LTBI among contacts [31]. We used a large range of LTBI prevalence (20–65%) in our sensitivity analysis, and there was no impact in the final conclusion.

Our study has a few limitations. We did not consider costs for repeated TST in case of lost reading and for diagnosing TST conversion. In addition, transmission of TB (secondary cases) was not accounted for. The option of not including transmission is justified by the short-term horizon and significant uncertainty that this variable can bring to the model. Multidrug resistance (MDR) cases were not considered because the prevalence is still modest in the country (<1%), despite the high rates of treatment default. [29] Finally, we performed a short-term analysis and did not incorporate gain in quantity or quality of life as the outcome measure. The choice of not including utility as an outcome was based on the lack of data on quality of life of TB patients in Brazil.

Generalization for other countries is difficult because local health system structure, financing and salaries as well as other parameters such as TB incidence and HIV-prevalence are widely variable. However, our results show that adoption of new technologies should not be based on apparently robust results on cost-effectiveness from other health systems. They should instead consider each country's scenarios and parameter values.

Conversely, the study has the advantage of considering the range of comprehensive systematic reviews for the most sensitive parameters, named prevalence of LTBI and accuracy of tests.

Health decision makers do not make choices based exclusively on economic analyses. Ethical, equity and protection from harm are important aspects to be considered. Although TST was the most cost-effective strategy, it had a non-monetary cost of treating a high number of subjects. On the other hand, TST is used for more than a century [13] and the benefits from IPT in TST-positive subjects is very well established [43], [44], [45]. Moreover, TST conversion detects recent TB infection, which has the highest risk of progression to active disease in a cohort of close contacts [4]. This is not yet the case for IGRA tests [46]. On the other hand, feasibility is another important issue. Training for TST is complex, time consuming and might incur in extra costs, not considered in the present study.

At present, our analysis suggests that unless a significant reduction in QFT-GIT costs is obtained, TST is currently the most cost-effective screening strategy for LTBI in the Brazilian scenario, despite the high number of subjects undergoing IPT. More studies on the long-term cost-effectiveness of this new technology, considering different subpopulations, are still needed.

Author Contributions

Helped with Data Collection: DC RF MB. Conceived and designed the experiments: RS MP AT RC. Performed the experiments: RS MP. Analyzed the data: RS MP AT DM. Contributed reagents/materials/analysis tools: STA DC RF MB. Wrote the paper: RS AT.


  1. 1. Raviglione M, Marais B, Floyd K, Lonnroth K, Getahun H, et al. (2012) Scaling up interventions to achieve global tuberculosis control: progress and new developments. Lancet 379: 1902–1913.
  2. 2. Dye C, Watt CJ, Bleed DM, Hosseini SM, Raviglione MC (2005) Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA 293: 2767–2775.
  3. 3. Dye C, Williams BG (2008) Eliminating human tuberculosis in the twenty-first century. J R Soc Interface 5: 653–662.
  4. 4. Menzies D, Gardiner G, Farhat M, Greenaway C, Pai M (2008) Thinking in three dimensions: a web-based algorithm to aid the interpretation of tuberculin skin test results. Int J Tuberc Lung Dis 12: 498–505.
  5. 5. International Union Against Tuberculosis Committee on Prophylaxis (1982) Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUATL trial: International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ: 555–564.
  6. 6. Comstock GW (1999) How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis 3: 847–850.
  7. 7. Trajman A, Long R, Zylberberg D, Dion MJ, Al-Otaibi B, et al. (2010) Factors associated with treatment adherence in a randomised trial of latent tuberculosis infection treatment. Int J Tuberc Lung Dis 14: 551–559.
  8. 8. Koch R (1982) Classics in infectious diseases. The etiology of tuberculosis: Robert Koch. Berlin, Germany 1882. Rev Infect Dis 4: 1270–1274.
  9. 9. Mantoux M (1912) La voie intradermique en tuberculinothérapie. Presse Med 20: 146–148.
  10. 10. Bierrenbach AL, Cunha SS, Barreto ML, Pereira SM, Rodrigues LC (2001) Skin test reactivity to mycobacterial antigens parallels the phylogenetic structure of their genus. Int J Tuberc Lung Dis 5: 656–663.
  11. 11. Cobelens FG, Menzies D, Farhat M (2007) False-positive tuberculin reactions due to non-tuberculous mycobacterial infections. Int J Tuberc Lung Dis 11: 934–935;author reply 935.
  12. 12. Menzies D (2000) What does tuberculin reactivity after bacille Calmette-Guerin vaccination tell us? Clin Infect Dis 31 Suppl 3S71–74.
  13. 13. Huebner RE, Schein MF, Bass JB Jr (1993) The tuberculin skin test. Clin Infect Dis 17: 968–975.
  14. 14. Watkins RE, Brennan R, Plant AJ (2000) Tuberculin reactivity and the risk of tuberculosis: a review. Int J Tuberc Lung Dis 4: 895–903.
  15. 15. Pai M, Zwerling A, Menzies D (2008) Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 149: 177–184.
  16. 16. Burgos JL, Kahn JG, Strathdee SA, Valencia-Mendoza A, Bautista-Arredondo S, et al. (2009) Targeted screening and treatment for latent tuberculosis infection using QuantiFERON-TB Gold is cost-effective in Mexico. Int J Tuberc Lung Dis 13: 962–968.
  17. 17. de Perio MA, Tsevat J, Roselle GA, Kralovic SM, Eckman MH (2009) Cost-effectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers. Arch Intern Med 169: 179–187.
  18. 18. Deuffic-Burban S, Atsou K, Viget N, Melliez H, Bouvet E, et al. (2010) Cost-effectiveness of QuantiFERON-TB test vs. tuberculin skin test in the diagnosis of latent tuberculosis infection. Int J Tuberc Lung Dis 14: 471–481.
  19. 19. Diel R, Nienhaus A, Loddenkemper R (2007) Cost-effectiveness of interferon-gamma release assay screening for latent tuberculosis infection treatment in Germany. Chest 131: 1424–1434.
  20. 20. Diel R, Wrighton-Smith P, Zellweger JP (2007) Cost-effectiveness of interferon-gamma release assay testing for the treatment of latent tuberculosis. Eur Respir J 30: 321–332.
  21. 21. Hardy AB, Varma R, Collyns T, Moffitt SJ, Mullarkey C, et al. (2010) Cost–effectiveness of the NICE guidelines for screening for latent tuberculosis infection: the QuantiFERON-TB Gold IGRA alone is more cost-effective for immigrants from high burden countries. Thorax 65: 178–180.
  22. 22. Kowada A, Takahashi O, Shimbo T, Ohde S, Tokuda Y, et al. (2008) Cost effectiveness of interferon-gamma release assay for tuberculosis contact screening in Japan. Mol Diagn Ther 12: 235–251.
  23. 23. Linas BP, Wong AY, Freedberg KA, Horsburgh Jr CR (2011) Priorities for Screening and Treatment of Latent Tuberculosis Infection in the United States. Am J Respir Crit Care Med.
  24. 24. Marra F, Marra CA, Sadatsafavi M, Moran-Mendoza O, Cook V, et al. (2008) Cost-effectiveness of a new interferon-based blood assay, QuantiFERON-TB Gold, in screening tuberculosis contacts. Int J Tuberc Lung Dis 12: 1414–1424.
  25. 25. Oxlade O, Schwartzman K, Menzies D (2007) Interferon-gamma release assays and TB screening in high-income countries: a cost-effectiveness analysis. Int J Tuberc Lung Dis 11: 16–26.
  26. 26. Pareek M, Watson JP, Ormerod LP, Kon OM, Woltmann G, et al.. (2011) Screening of immigrants in the UK for imported latent tuberculosis: a multicentre cohort study and cost-effectiveness analysis. Lancet Infect Dis.
  27. 27. Pooran A, Booth H, Miller RF, Scott G, Badri M, et al. (2010) Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysis. BMC Pulm Med 10: 7.
  28. 28. Denkinger CM, Dheda K, Pai M (2011) Guidelines on interferon-gamma release assays for tuberculosis infection: concordance, discordance or confusion? Clin Microbiol Infect 17: 806–814.
  29. 29. Programa Nacional de Controle da Tuberculose (2010) Manual de Recomendações para o Controle da Tuberculose no Brasil.
  30. 30. Zwerling A, Behr MA, Verma A, Brewer TF, Menzies D, et al. (2011) The BCG World Atlas: A Database of Global BCG Vaccination Policies and Practices. PLoS Med 8: e1001012.
  31. 31. Morrison J, Pai M, Hopewell PC (2008) Tuberculosis and latent tuberculosis infection in close contacts of people with pulmonary tuberculosis in low-income and middle-income countries: a systematic review and meta-analysis. Lancet Infect Dis 8: 359–368.
  32. 32. Schwartzman K, Menzies D (2000) Tuberculosis screening of immigrants to low-prevalence countries. A cost-effectiveness analysis. Am J Respir Crit Care Med 161: 780–789.
  33. 33. Dowdy DW, Lourenco MC, Cavalcante SC, Saraceni V, King B, et al. (2008) Impact and cost-effectiveness of culture for diagnosis of tuberculosis in HIV-infected Brazilian adults. PLoS One 3: e4057.
  34. 34. Steffen R, Menzies D, Oxlade O, Pinto M, de Castro AZ, et al. (2010) Patients' costs and cost-effectiveness of tuberculosis treatment in DOTS and non-DOTS facilities in Rio de Janeiro, Brazil. PLoS One 5: e14014.
  35. 35. Slowiak PF (1985) Life cycle costing in hospitals. How to provide quality systems cost effectively. Hosp Top 63: 31–33.
  36. 36. Edejer TT-T, World Health Organization. (2003) Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization. xiii, 312, 318 p.
  37. 37. Ministerio da Saúde (2010) Série histórica do número de casos novos de tuberculose. Brasil, Regiões e Unidades Federadas de residência por ano diagnóstico (1990 a 2010).
  38. 38. Gold MR (1996) Cost-effectiveness in health and medicine. New York: Oxford University Press. xxiii, 425 p.
  39. 39. Salpeter SR, Sanders GD, Salpeter EE, Owens DK (1997) Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk-benefit and cost-effectiveness analysis. Ann Intern Med 127: 1051–1061.
  40. 40. Mancuso JD, Niebuhr DW, Frick KD, Keep LW, Anderson KM (2011) Cost-effectiveness analysis of targeted and sequential screening strategies for latent tuberculosis. Int J Tuberc Lung Dis 15: 1223–1230, i.
  41. 41. Kowada A (2010) Cost effectiveness of interferon-gamma release assay for tuberculosis screening of rheumatoid arthritis patients prior to initiation of tumor necrosis factor-alpha antagonist therapy. Mol Diagn Ther 14: 367–373.
  42. 42. Kowada A, Deshpande GA, Takahashi O, Shimbo T, Fukui T (2010) Cost effectiveness of interferon-gamma release assay versus chest X-ray for tuberculosis screening of BCG-vaccinated elderly populations. Mol Diagn Ther 14: 229–236.
  43. 43. Nolan CM (2003) Isoniazid for latent tuberculosis infection: approaching 40 and reaching its prime. Am J Respir Crit Care Med 168: 412–413.
  44. 44. Tsevat J, Taylor WC, Wong JB, Pauker SG (1988) Isoniazid for the tuberculin reactor: take it or leave it. Am Rev Respir Dis 137: 215–220.
  45. 45. Samandari T, Agizew TB, Nyirenda S, Tedla Z, Sibanda T, et al. (2011) 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet 377: 1588–1598.
  46. 46. Pai M, O'Brien R (2007) Serial testing for tuberculosis: can we make sense of T cell assay conversions and reversions? PLoS Med 4: e208.
  47. 47. Lemos AC, Matos ED, Pedral-Sampaio DB, Netto EM (2004) Risk of tuberculosis among household contacts in Salvador, Bahia. Braz J Infect Dis 8: 424–430.
  48. 48. LoBue PA, Moser KS (2003) Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med 168: 443–447.
  49. 49. Kopanoff DE, Snider DE Jr, Caras GJ (1978) Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis 117: 991–1001.
  50. 50. Diel R, Goletti D, Ferrara G, Bothamley G, Cirillo D, et al. (2011) Interferon-gamma release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J 37: 88–99.